FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities-Reference-Cited by-同舟云学术

FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities

Published:2016-08-04 Issue:12 Volume:1 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Rais Rana,Jiang Weiwei,Zhai Huihong,Wozniak Krystyna M.,Stathis Marigo,Hollinger Kristen R.,Thomas Ajit G.,Rojas Camilo,Vornov James J.,Marohn Michael,Li Xuhang,Slusher Barbara S.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference60 articles.

1. Unravelling the pathogenesis of inflammatory bowel disease

2. The fundamental basis of inflammatory bowel disease

3. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

4. Inflammatory Bowel Disease

5. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the essential roles of glutamate carboxypeptidase 2 orthologs in Caenorhabditis elegans;Bioscience Reports;2024-01

2. Glutamate carboxypeptidase II;Metalloenzymes;2024

3. PSMA-Targeted PET Radiotracer [18F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease;Clinical and Experimental Gastroenterology;2023-12

4. Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2023-10

5. A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis;Science Translational Medicine;2023-08-09